[go: up one dir, main page]

BRPI0513935A - formulações de compostos de 2-amina-1,3-propanodiol - Google Patents

formulações de compostos de 2-amina-1,3-propanodiol

Info

Publication number
BRPI0513935A
BRPI0513935A BRPI0513935-0A BRPI0513935A BRPI0513935A BR PI0513935 A BRPI0513935 A BR PI0513935A BR PI0513935 A BRPI0513935 A BR PI0513935A BR PI0513935 A BRPI0513935 A BR PI0513935A
Authority
BR
Brazil
Prior art keywords
amine
compound formulations
formulations
propanediol compound
propanediol
Prior art date
Application number
BRPI0513935-0A
Other languages
English (en)
Inventor
Thitiwan Buranachokpaisan
Rose-Marie Dannenfelser
Ping Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0513935A publication Critical patent/BRPI0513935A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçõES DE COMPOSTOS DE 2-AMINA-1,3-PROPANODIOL. A presente invenção refere-se a formulações farmacêuticas de concentrado compreendendo compostos de 2-amina-1,3-propanodiol, análogos dos mesmos e sais dos mesmos, particularmente 2-amina-2-¢2-(4-octilfenil)etil!-propano-1,3-diol ou um sal farmaceuticamente aceitável do mesmo em um solvente orgânico ou solvente semi-aquoso e métodos para a administração do concentrado não diluído e diluído são fornecidos.
BRPI0513935-0A 2004-07-30 2005-07-29 formulações de compostos de 2-amina-1,3-propanodiol BRPI0513935A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59299104P 2004-07-30 2004-07-30
PCT/EP2005/008267 WO2006010630A1 (en) 2004-07-30 2005-07-29 Compound formulations of 2-amino-1, 3-propanediol compounds

Publications (1)

Publication Number Publication Date
BRPI0513935A true BRPI0513935A (pt) 2008-05-20

Family

ID=35058068

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513935-0A BRPI0513935A (pt) 2004-07-30 2005-07-29 formulações de compostos de 2-amina-1,3-propanodiol

Country Status (14)

Country Link
US (3) US20080096972A1 (pt)
EP (2) EP1773307B8 (pt)
JP (1) JP5214966B2 (pt)
KR (1) KR101174930B1 (pt)
CN (1) CN1993115B (pt)
AU (2) AU2005266449B2 (pt)
BR (1) BRPI0513935A (pt)
CA (1) CA2574664C (pt)
ES (1) ES2527055T3 (pt)
MX (1) MX2007001236A (pt)
PL (1) PL1773307T3 (pt)
PT (1) PT1773307E (pt)
RU (2) RU2402324C2 (pt)
WO (1) WO2006010630A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010630A1 (en) * 2004-07-30 2006-02-02 Novartis Ag Compound formulations of 2-amino-1, 3-propanediol compounds
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
CA2752003A1 (en) * 2009-02-24 2010-09-02 Novartis Ag Ceramide-analogous metabolites
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
RU2530532C1 (ru) * 2013-03-26 2014-10-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ) Устройство плавного пуска асинхронного двигателя
JP6316422B2 (ja) 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
CN103724215A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 2-氨基-2-[2-(4-辛基苯基)乙基]-1,3-丙二醇的新型衍生物及其应用
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575153B2 (en) * 1984-04-09 1988-07-21 Du Pont Merck Pharmaceutical Company, The Pharmaceutical compositions and method for treatment for prophylaxis of cardiac disorders
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AU6001790A (en) * 1989-08-02 1991-02-07 Warner-Lambert Company Formulations of phenytoin sodium for intravenous administration
ATE172711T1 (de) * 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
IL111008A (en) * 1993-09-30 1999-10-28 American Home Prod Rapamycin formulations for intravenous injection and their preparation
WO1996006068A1 (fr) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Compose benzenique et son utilisation medicale
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
AU735406B2 (en) * 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
ES2237970T3 (es) 1998-11-11 2005-08-01 Novartis Ag Produccion de 2-amino-2-(2-(4-alquil c2-20-fenil)etil)propano-1,3-dioles.
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JP4217620B2 (ja) 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
EP1470137B1 (en) * 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
JP4709488B2 (ja) * 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
DE10226255A1 (de) 2002-06-13 2003-12-24 Bosch Gmbh Robert Schutzvorrichtung
ATE414508T1 (de) * 2003-04-08 2008-12-15 Novartis Pharma Gmbh Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
WO2006010630A1 (en) * 2004-07-30 2006-02-02 Novartis Ag Compound formulations of 2-amino-1, 3-propanediol compounds

Also Published As

Publication number Publication date
RU2007107171A (ru) 2008-09-10
CN1993115B (zh) 2011-12-28
RU2468793C2 (ru) 2012-12-10
WO2006010630A1 (en) 2006-02-02
EP2829268A1 (en) 2015-01-28
EP1773307B1 (en) 2014-10-15
US20080096972A1 (en) 2008-04-24
AU2005266449B2 (en) 2009-10-08
RU2402324C2 (ru) 2010-10-27
EP1773307A1 (en) 2007-04-18
AU2009217456A1 (en) 2009-10-15
MX2007001236A (es) 2007-03-23
EP1773307B8 (en) 2014-12-17
KR20070042988A (ko) 2007-04-24
JP5214966B2 (ja) 2013-06-19
US20140094522A1 (en) 2014-04-03
KR101174930B1 (ko) 2012-08-17
JP2008508222A (ja) 2008-03-21
PL1773307T3 (pl) 2015-03-31
AU2005266449A1 (en) 2006-02-02
CA2574664C (en) 2013-01-15
CA2574664A1 (en) 2006-02-02
US20160101179A1 (en) 2016-04-14
CN1993115A (zh) 2007-07-04
RU2010124600A (ru) 2011-12-27
PT1773307E (pt) 2015-01-14
ES2527055T3 (es) 2015-01-20

Similar Documents

Publication Publication Date Title
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
CR10195A (es) "sistemas de administración de plaguicidas "
BRPI0512237A (pt) cis-imidazolinas
EA200900184A1 (ru) 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
BR112014009190A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
EP1829863A4 (en) ARYLALKANSÄUREDERIVAT
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
BRPI0513819A (pt) inibidores de hsp90
BRPI0513935A (pt) formulações de compostos de 2-amina-1,3-propanodiol
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0616659A8 (pt) droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
AR059357A1 (es) Formulaciones farmaceuticas
BRPI0513379A (pt) derivados de sulfonamida
DE602005027540D1 (de) Feste formulierungen von ospemifen
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
UY30788A1 (es) Compuestos quimicos
ATE537822T1 (de) Antidepressivum
BRPI0410044B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]